Absentia Labs

Absentia Labs is an AI-biology company that develops foundation models designed to predict the behavior of medicines within the human body. By leveraging biological, chemical, and clinical data, the company's in-silico platform aims to transform drug discovery from an experimental science into a predictive, computable process. Their technology models drug efficacy and safety, helping to identify organ-specific risks early and providing a scalable alternative to traditional, slower, and often less reliable methods of preclinical testing. The company's work has been recognized by organizations such as the FDA, which accepted their AI-driven digital liver model into its ISTAND qualification program.

This technology is intended to help pharmaceutical companies and researchers streamline drug development, reduce costs, and minimize reliance on animal testing. By enabling more accurate, data-driven decisions in the early stages of therapeutic research, Absentia Labs aims to accelerate the delivery of safer medicines to patients and improve overall success rates in drug development. Founded as a spin-out from MIT research, the Boston-based startup is focused on addressing fundamental bottlenecks in the pharmaceutical industry by applying frontier AI research to practical, real-world biological challenges.